Amount
Latest price
$117.33
(£1.00 = $1.295)
Number of shares (est.)
0
Market Cap
$36.123B
P/E ratio
29.10
EPS
$4.354
Beta
1.17
Dividend rate
$0.956
Dividend yield
0.75%
Agilent Technologies, Inc. is engaged in providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company’s life sciences and applied markets segment provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the cell analysis, advanced manufacturing partnerships contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, genomics and biomolecular analysis businesses. The Agilent CrossLab segment offers a service portfolio that includes repairs, parts, maintenance, installations and various other custom services to support the laboratory operations. It also offers contract development and manufacturing organization (CDMO) services.
CEO
Mr. Padraig McDonnell
Employees
17,900
Sector
Industrials
Company HQ
SANTA CLARA, United States of America
Website
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusiv.
Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare Conference.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.